Bulletin of Experimental Biology and Medicine

, Volume 135, Issue 5, pp 478–481

Expression of Flt-1 and Flk-1 Receptors for Vascular Endothelial Growth Factor on Tumor Cells as a New Prognostic Criterion for Locally Advanced Breast Cancer

Authors

  • L. G. Zhukova
    • N. N. Blokhin Russian Research Center for OncologyRussian Academy of Medical Sciences
  • N. V. Zhukov
    • N. N. Blokhin Russian Research Center for OncologyRussian Academy of Medical Sciences
  • M. R. Lichinitser
    • N. N. Blokhin Russian Research Center for OncologyRussian Academy of Medical Sciences
Article

DOI: 10.1023/A:1024975627843

Cite this article as:
Zhukova, L.G., Zhukov, N.V. & Lichinitser, M.R. Bulletin of Experimental Biology and Medicine (2003) 135: 478. doi:10.1023/A:1024975627843

Abstract

We studied expression of Flt-1 and Flk-1 receptors on tumor cells obtained from 83 patients with locally advanced breast cancer after neoadjuvant chemotherapy. The mean period of observations was 32.3 months. The median recurrence-free survival periods for Flt-1+ and Flt-1- patients were 55 and 32 months, respectively (p=0.0064). The overall survival periods for Flt-1- and Flt-1+ patients were 45 and 67.6 months, respectively (p=0.014). The mean recurrence-free survival periods for Flk-1+ and Flk-1- patients were 40.8 and 60.9 months, respectively (p=0.035). Expression of VEGF had no prognostic value. Our results show that overexpression of Flk-1 on breast cancer cells in patients receiving neoadjuvant chemotherapy is associated with a poor prognosis. By contrast, overexpression of Flt-1 improves survival.

breast cancerVEGF, Flt-1, Flk-1

Copyright information

© Plenum Publishing Corporation 2003